IKS
Small CapInventurus Knowledge Solutions Limited
IT
IKS is in the business of delegating chore tasks for US healthcare providers, operating a platform system of action. It aims to free providers from data entry and regulatory burdens, leveraging AI to automate tasks like clinical documentation, coding, and patient engagement. The company targets a $260B TAM, with an outsourced TAM of $35B growing at 12%.
One read, four checks
75+ is strong, 60-74 is usable, 45-59 is mixed, and below 45 needs caution. These are research lenses, not buy/sell instructions.
Mixed fundamentals, management trust is supportive, price trend is neutral, and recent execution is consistent.
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
low confidence · 0/0 claims checked
Timing lens: price trend and sector relative strength.
Rolling lens: recent quarterly delivery, not the latest single-result score.
Quarter ended 31 Mar 2026
Excellent · 90/100Rev +19% YoY · PAT +39% YoY · margin expansion · +5% QoQ · operating leverage
| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹858 Cr | +18.5% | +5.3% |
| EBITDA | ₹295 Cr | +30.5% | +5.7% |
| Operating margin | 34.0% | +300 bps | +0 bps |
| PAT | ₹206 Cr | +39.2% | +12.6% |
| PAT margin | 24.0% | +357 bps | +156 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Where growth can come from, and what can break the case
IKS Health reports strong Q4 FY26 with 18.5% YoY revenue growth (13% CC USD) and 33% YoY EBITDA growth, driven by non-linearity from AI-native platform and AQuity integration. Full-year FY26 revenue grew 20% YoY, EBITDA 38% YoY, and PAT 48% YoY.
Management's strategic pivot for AQuity cross-sell and continued AI-native platform development are yielding results, evidenced by strong Q4 and FY26 financials. The proposed TruBridge acquisition and ARAI acqui-hire are significant steps to build a data moat and accelerate AI capabilities, reinforcing the long-term platform strategy.
AI-Native Agentic Platform
Moving to an AI-native agentic platform manifest, with launches like Scribble Select and MyCare Hub, driving autonomy in clinical documentation, coding, and patient engagement.
AQuity Cross-Sell & Integration
Figured out the plot to truly unlock cross-sell motion in AQuity customer base with stratified GTM for mid-sized (platform) and large (land & expand point solutions) health systems.
TruBridge Acquisition (Proposed)
Proposed acquisition to build an integrated system of record and system of action for the rural healthcare market, leveraging patient data for AI training corpus and native workflow orchestration.
Outcome-Based Value Proposition
Ability to align outcomes with provider's outcomes, demonstrating transformative financial results like $3M NEVA earnings in Palomar, making the value proposition more compelling.
Technology Workforce Expansion
Fastest growing component of workforce is technology, now 550 employees, focused on proprietary technology and AI engineering.
Sales & Marketing Headcount Growth
Sales and marketing headcount now stands at 66 FTEs and growing, reflecting increased investment.
ARAI Acqui-hire
Acqui-hire of ARAI, a company founded by two scientists, to accelerate AI journey, build neuro-symbolic models, and develop proprietary knowledge graphs for clinical reasoning.
Growing US Healthcare TAM
US healthcare is a $5 trillion+ industry, creating a TAM of north of $260 billion for delegable tasks, with outsourced TAM growing at 12%.
AI as a Differentiator
AI makes code generation cheaper and more reliable, which is a huge tailwind for us as we build our own AI and technology orchestrates actions.
Strategic Partnerships
Partnership with Certilytics aims to reduce friction and cost in revenue cycle between payers and providers through collaborative technology.
Epic Connection Hub Integration
Autonomous coding, revenue cycle engine, and MyCare Hub are now available in Epic Connection Hub, important for penetrating large health systems.
Seasonal Weakness in Q1 Calendar
Q1 calendar tends to be seasonally the weakest quarter for US providers due to insurance deductible resets and low patient footfalls, exacerbated by intense winter.
AQuity Customer Shrinkage
Some AQuity customers with more than $1M revenue saw shrinkage as we offshored and offered some discounts.
TruBridge Integration Risk
The TruBridge acquisition is an 'equal size deal completely financed by debt,' requiring successful integration and debt reduction over three to four years.
Regulatory Approval for TruBridge
Regulatory approvals for the TruBridge transaction are still work in progress, with additional transaction expenses expected in Q1.
AI Hallucinations/Inaccuracies
In healthcare, we cannot afford hallucinations and inaccuracies; some edge cases will always require human-in-the-loop, even with advanced AI.
Reliance on Foundational LLMs
Over a period of time, the cost of compute for commercially available foundational models is important; building proprietary SLMs reduces this reliance.
What management said, and what results must prove
Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.
Both YoY and QoQ comparisons are relevant. YoY reflects the overall growth trajectory and market share gains in a growing TAM. QoQ is important for assessing sequential momentum, especially in headcount efficiency and margin expansion, and for understanding seasonal impacts on US healthcare providers.
Revenue Growth (YoY INR)
Revenue grew 18.5% year-on-year, coming in at INR857 crores for Q4 FY26.
Revenue Growth (YoY Constant Currency USD)
In constant currency terms, Q4 FY26 revenue growth was about 13% in USD terms.
EBITDA Margin
EBITDA of INR300 crores, which is about 35% EBITDA for Q4 FY26.
PAT Margin
Profit after tax for Q4 FY26 came in at about INR206 crores, which is about 24%.
True North Vision FY30
True North vision to take EBITDA from INR1,000 crores (LTM Dec 2025) to about INR3,000 crores in FY30, aiming for near zero net debt.
AI Training Corpus as Moat
TruBridge acquisition will provide access to patient data, enabling an AI training corpus for effective agentic orchestration and building proprietary SLMs.
Glass Box AI for Healthcare
Introducing 'glass box AI' for transparent, traceable, and auditable AI outcomes, crucial for healthcare where accuracy and understanding AI's reasoning are paramount.
Accelerated AI Journey
ARAI acqui-hire will accelerate the journey to build neuro-symbolic models and proprietary knowledge graphs, reducing reliance on external foundational models.
Numbers and claims to verify in the next filings
| Checkpoint | Current evidence | What to verify next |
|---|---|---|
| TruBridge Acquisition Close | Awaiting close of transaction; regulatory approvals are work in progress. | Successful closure of the TruBridge transaction and initial integration progress. |
| AQuity Cross-Sell Execution | Pivoted GTM strategy for large health systems (land & expand) and mid-sized (platform). | Continued manifestation of cross-sell strategy in AQuity customer base over next several quarters. |
| AI-Native Platform Utilization | Launched Scribble Select (multi-variant ambient AI scribing) and MyCare Hub (multi-agent patient engagement). | Fundamentally different level of utilization by doctors for Scribble Select and market traction for MyCare Hub. |
| Net Debt Reduction | Reduced debt from peak INR850 crores to INR251 crores as of March 31, 2026. | Progress towards near zero net debt by FY30, especially post-TruBridge debt financing. |
Verification checkpoints are IndiaPulse research interpretation, not investment advice.
Trend score and candlestick chart
55NeutralSMA20 +4.3% / mo · near 52W high
Technical chart
IKSweekly · 3Y-10.7%Technical trend read
NeutralTrend is undirectional — long-term trend unclear. RSI 56.
- SMA20 rising (~4.1% over last month) — short-term momentum positive.
- RSI(14) at 56 — sideways, no extreme reading.
- MACD above signal but histogram contracting — bullish momentum cooling.
- 5% off 52W high · 33% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Valuation, score drivers, trust methodology, financials, and peers
Use these sections after reviewing the decision summary, latest result, thesis, management accountability, and technical timing above.
Fundamental score breakdown
FAIR VALUEWhy this score?
Top U-Score contributors and drags from the latest stored fundamentals.
Positive drivers
- Piotroski is strong at 8/9.
- Quality contributes 19/20 to the score.
- Growth contributes 18/25 to the score.
Main drags
- Fair-value margin of safety is negative at -11.3%.
- Valuation is weaker at 0/30; verify the latest quarterly trend.
- Cash flow is weaker at 5/10; verify the latest quarterly trend.
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Score history
12 stored score snapshots. Latest stored move: +0 points.
Factor attribution
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
High Trust: Claim history is still being built. It ranks around the 98th percentile of the scored universe and 98th percentile within IT. No major sub-score weakness stands out.
High Trust Lite: Promoter holding is 63.7%.
Management behaviour ranks as unusually reliable. Still verify valuation and cycle risk.
overall median 67 · IT: 98th pctile, median 68 · Small: 99th pctile, median 65
46 documents indexed, but claim history is not strong enough yet.
0 claims extracted · No contradicted claim yet
How to read this Trust Score
High Trust · low confidenceRead Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Trust positives
- ▸Promoter holding is 63.7%.
- ▸Promoter pledge is zero.
- ▸FCF yield is positive at 1.6%.
- ▸6 years of positive FCF.
Trust risks
- ▸No major Trust Lite risk flags.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Intrinsic value
Fundamentals
Valuation
- P/E
- 39.50
- P/B
- 12.66
- EV/EBITDA
- 24.25
- Market Cap
- 28475.00Cr
Profitability
- ROE
- 40.30%
- ROCE
- 36.90%
- ROA
- 20.02%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 42.00%
- EPS 5Y
- 34.00%
- Revenue 3Y
- 46.00%
- EPS 3Y
- 30.00%
Balance Sheet
- Debt/Equity
- 0.34
- Interest Coverage
- 15.46×
- Altman Z
- 8.96
- Book Value
- 131.00
Cash Flow
- FCF Yield
- 1.63%
- FCF Positive Y
- 6/5
- OCF
- 674.00 Cr
- EPS TTM
- 42.03
Shareholding
- Promoter Hold
- 63.72%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 65%
Financial History
Updated 9/6/2026
Revenue
₹ CrNet Profit
₹ CrReturn on Equity
%Peers
Business-comparable peers in IT — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.